🌟 Supporting Rare Disease Day 2025 🌟
February 28, 2025
At
Pharmidex, we stand in solidarity with patients, families, and researchers on
Rare
Disease
Day.
Today, we reinforce our commitment to advancing drug discovery and development for rare diseases because every patient deserves hope, innovation, and better treatment options.
With our expertise in in silico drug discovery, ADME-PK, bioanalysis, and preclinical research, we work tirelessly to support biotech and pharma companies in their mission to bring life-changing therapies to those affected by rare conditions.
Together, we can accelerate progress and make a difference. 💙✨
We’re Hiring! Senior/Principal Scientist–In Vivo Pharmacologist
We’re delighted to welcome Gabrielle Georgiou and Dr. Mohammed Ahmad from the University of Hertfordshire as they begin their first experience in a scientific CRO environment here at Pharmidex ! This partnership is an exciting step in fostering early-career scientific talent by offering hands-on exposure to real-world drug discovery and preclinical research. A big thank you to the University of Hertfordshire for partnering with us to support the next generation of innovators. We’re proud to play a role in shaping future leaders in science through meaningful, practical learning opportunities. 👩🔬 👨🔬 Welcome to the team, Gabrielle and Mohammed!
At Pharmidex , we offer Brief Access Taste Aversion (BATA) testing, which is a behavioural assay that quantifies how test subjects respond to different compounds or formulations by measuring lick response and aversion. This helps identify: ✅ Bitter-tasting APIs ✅ Unpalatable excipients ✅ The success of taste-masking strategies ✅ Formulation-dependent compliance risks Get in touch if you’re developing oral formulations, paediatric drugs, or repurposing bitter APIs, this could be the data your IND package needs.
